GLP-1 Qualification: Medical Criteria & Biomarker Context

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are prescribed when patients meet specific clinical criteria: typically BMI ≥30 kg/m², or BMI ≥27 with weight-related conditions like hypertension or type 2 diabetes. The FDA-approved branded medications (semaglutide, tirzepatide) have established qualification guidelines, though compounded versions follow similar clinical frameworks with provider discretion.

Beyond standard metrics, understanding your metabolic profile, insulin sensitivity, and genetic predispositions can support a more informed conversation with your provider about whether GLP-1 therapy aligns with your health goals. PlexusDx emphasizes precision medicine—knowing your individual context helps personalize the qualification and treatment decision process.

Standard Clinical Criteria for GLP-1 Eligibility

FDA guidance and clinical practice establish baseline qualification thresholds. Adults with BMI ≥30 kg/m² (or ≥27 with comorbidities) generally meet initial criteria. Type 2 diabetes diagnosis alone qualifies patients regardless of BMI. Providers also assess cardiovascular risk factors, kidney function, and thyroid history before initiating therapy.

Weight-related comorbidities that support qualification include hypertension, dyslipidemia, sleep apnea, and metabolic syndrome. Cardiovascular disease or prior cardiac events may strengthen the case for GLP-1 use. Each provider evaluates the full clinical picture rather than BMI alone, considering medication interactions, contraindications, and patient readiness for injectable or oral therapy.

Key Medical Factors That Influence Qualification

Qualification involves more than weight metrics. Metabolic markers, glucose tolerance, kidney function (eGFR), liver enzymes, and thyroid status inform safety and suitability. Providers may order baseline labs to rule out contraindications such as personal or family history of medullary thyroid carcinoma, severe pancreatitis, or uncontrolled diabetic retinopathy.

Clinical Factor	Impact on GLP-1 Eligibility
BMI ≥30 or ≥27 with comorbidity	Primary qualification criterion; foundational eligibility marker
Type 2 diabetes diagnosis	Qualifies regardless of BMI; core indication for GLP-1 therapy
Cardiovascular disease or prior cardiac event	Strengthens case; may support earlier intervention and closer monitoring
eGFR <15 mL/min/1.73m²	Relative or absolute contraindication; requires specialized provider assessment
Personal/family history of medullary thyroid carcinoma	Contraindication; GLP-1 medications carry black box warning for this population
Uncontrolled hypertension (SBP >180 mmHg)	May defer treatment until controlled; requires baseline management optimization
Fasting glucose >126 mg/dL or HbA1c >6.5%	Supports diabetes diagnosis and strengthens qualification rationale

Biomarker Context and Metabolic Predisposition

Qualification extends beyond diagnostic thresholds when providers consider underlying metabolic dysfunction. Insulin resistance, evidenced by elevated fasting insulin or HOMA-IR score >2.5, may predict stronger GLP-1 response and support earlier treatment initiation. Inflammatory markers like C-reactive protein and lipid ratios add clinical texture to the eligibility conversation.

Genetic predispositions in peptide pathways—such as variants in the GLP1R, GIPR, FTO, or MC4R genes—may help provide context for individual metabolic patterns and treatment suitability. Understanding whether your genetics predict increased appetite dysregulation or reduced insulin secretion can support a more personalized qualification discussion with your provider, though genetics alone do not determine eligibility.

Contraindications, Safety Considerations, and Provider Assessment

Absolute contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN2). Relative contraindications—such as severe renal impairment, uncontrolled pancreatitis history, or severe gastroparesis—require provider judgment and may not exclude treatment but demand closer monitoring. Pregnancy is a contraindication; women of childbearing age should discuss contraception plans before starting GLP-1 therapy.

Qualification is ultimately a provider determination. A thorough history, physical exam, and baseline labs (glucose, HbA1c, kidney function, liver enzymes, lipids, thyroid-stimulating hormone) guide the decision. Your provider will assess medication interactions, previous weight-loss attempts, motivation for behavioral change, and readiness for potential side effects. Open conversation about your health goals and concerns is essential to establish true clinical eligibility.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for your metabolic profile by analyzing predispositions in GLP-1 receptor (GLP1R), GIPR (glucose-dependent insulinotropic polypeptide receptor), FTO (fat mass and obesity-associated gene), and MC4R (melanocortin-4 receptor) pathways. These genetic variants can reveal whether your biology predicts heightened appetite regulation challenges, altered insulin secretion patterns, or weight-loss resistance—factors that inform a more nuanced qualification conversation with your provider.

The test reveals genetic predispositions, not exact medication response. Variants such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 help illustrate whether your metabolic machinery may benefit from GLP-1 pathway activation. This context should be interpreted with a qualified healthcare provider as one piece of a comprehensive eligibility assessment, never as a standalone qualification tool or guarantee of treatment success.

Understanding your genetic predispositions alongside standard clinical criteria (BMI, glucose status, comorbidities, kidney function) can support a richer conversation with your provider about why GLP-1 therapy may be appropriate for you and which formulation (injectable vs. oral, higher vs. lower starting dose) might align best with your genetics and medical history.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.